Recent Executive Leadership Changes Across Global Pharmaceutical and MedTech Companies Including Johnson & Johnson, BD, and Varian

Johnson & Johnson Medical

Kevin Chen (Chen Chuhui), General Manager of Johnson & Johnson Medical Technology China Cardiovascular and Professional Solutions Division, and Head of External Affairs and Market Access, has submitted his resignation to the company to pursue external development opportunities. Chen Chuhui joined Johnson & Johnson in 2009 and successively held management positions in the Ethicon ASP Division, Endo Division’s Harmonic Scalpel business, Gynecare Division, and Mentor Division. After returning to Johnson & Johnson again in 2015, Chen Chuhui also took on important leadership roles such as Head of Channel Management, Strategic Customers, Operations, and Professional Education. On March 31, 2023, the former General Manager of Johnson & Johnson Medical Technology China Cardiovascular and Professional Solutions Division, Chen Xi, resigned. Afterwards, Chen Chuhui took over the position.

Varian

Varian announced that Dr. Xiaozhang, Senior Vice President of Varian globally and President of Greater China, will retire. Effective October 1, 2024, Christine Qian, General Manager of Varian Interventional Solutions in China, will be appointed as the head of Varian's Greater China region. Prior to joining Varian, Christine Qian held senior management positions at well-known companies such as Johnson & Johnson Medical, Boston Scientific, B. Braun, and Stryker. In 2021, Christine Qian was appointed as the General Manager of Varian’s Interventional Solutions in China.

B. Braun Medical

B. Braun Medical China Appoints New Managing Director. Mr. Yeong Lih Chyun, Managing Director of B. Braun Medical Supply Chain and Head of Business Excellence for the Asia-Pacific region, has been appointed as the Managing Director for Greater China, effective August 1st. Mr. Yeong Lih Chyun will oversee B. Braun Medical's operations in Greater China and will continue to serve as a member of the Asia-Pacific Board. Until further notice, Mr. Yeong Lih Chyun will also retain his roles as Managing Director of B. Braun Medical Supply Chain and Head of Business Excellence for the Asia-Pacific region. Mr. Yeong Lih Chyun brings over 20 years of experience in the medical device industry, with more than 19 years at B. Braun Medical.

Hengrui Pharma

Hengrui Pharma Announces Departure of Two Vice Presidents: Jiang Sumei and Wang Hongsen Step Down Due to Personal Reasons

Innovent Bio

Innovent Bio President Yongjun Liu Resigns; Founder, Chairman and CEO Dechao Yu Now Oversees R&D Operations. Yongjun Liu previously served as a senior scientist at Schering-Plough and as a principal scientist at DNAX Research Institute, a biotechnology subsidiary of Schering-Plough. In 2014, Yongjun Liu was appointed Chief Scientific Officer and Global Head of Research at MedImmune, the global biologics research and development subsidiary of AstraZeneca. In 2016, he became Global Head of Research at Sanofi. In 2020, Yongjun Liu joined Innovent Bio, where he was responsible for the company's global R&D, pipeline strategy, business development, and international operations.

JW Therapeutics

JW Therapeutics Announces the Appointment of Mr. Liu Min as Chief Executive Officer. Mr. Liu Min will also serve as an Executive Director on the company’s Board of Directors. Dr. Li Yiping has stepped down as CEO of the company, but during the transition period, he will continue to serve as Chairman of the Board. Prior to joining JW Therapeutics, Mr. Liu Min served as Chief Commercial Officer at Innovent Bio. Before that, he held the position of Vice President at Roche in China. Earlier in his career, Mr. Liu also held management positions at several well-known multinational pharmaceutical companies.

Rongchang Bio

Rongchang Bio appoints Dr. Lushe He as Chief Strategy Officer. While serving as Chief Strategy Officer, Dr. Lushe He will continue to serve as a member of the board and retain his status as a core technical expert, but will no longer hold the positions of Chief Medical Officer or senior management. Dr. Lushe He joined the U.S. FDA in 1999, responsible for the review and approval of new drug clinical trials. From 1999 to 2016, he held various positions at the FDA's Center for Drug Evaluation and Research, including Medical Director, Team Leader, and Acting Deputy Director, with 17 years of clinical review and approval experience at the U.S. FDA.

Conba

Conba Completes Leadership Change and Business Registration Update. Hu Jiqiang Steps Down as Legal Representative and Chairman, Succeeded by Jiang Yi; Multiple Other Key Personnel Also Changed.

Shanghai Modern Pharma

Shanghai Modern Pharmaceutical Co., Ltd. announced that the company's board of directors had received written resignation reports from both Dong Zenghe, the chairman of the board, and Lian Wanyong, a director and president. Dong Zenghe has applied to step down from his positions as director and chairman, while Mr. Lian Wanyong has applied to resign from his roles as director and president. Meanwhile, Shanghai Modern Pharmaceutical announced the appointment of Liu Yong as the company’s president, with his term lasting until the end of the eighth board of directors’ tenure. Additionally, during the vacancy of the chairman position, Liu Yong will temporarily assume the responsibilities of the chairman.

BD Medical

BD, a globally leading medical technology company, announced that Michael Feld will officially assume the role of Executive Vice President and President of the Life Sciences segment starting August 20, 2024. He will also join the company's senior leadership team based in Franklin Lakes, New Jersey.

Bayer

BioMarin Announces Appointment of Greg Friberg, M.D., as Executive Vice President and Chief Research & Development Officer, Replacing Hank Fuchs, M.D.; James Sabry, M.D., Appointed as Executive Vice President and Chief Business Officer. Dr. Friberg joins BioMarin from Amgen, where he served as Vice President of Global Medical Affairs for Rare Diseases. Dr. Sabry joins BioMarin from Roche/Genentech, most recently serving as Executive Vice President and Global Head of Roche Partnering.

Hansa Biopharma

Hansa Biopharma announced that Matthew Shaulis, Chief Commercial Officer and President of the U.S., has decided to leave the company at the end of September. The commercial leadership team will report to President and CEO Søren Tulstrup, and the search for a new CEO and U.S. President is underway.

CVS Health

CVS Health announced that Heidi Capozzi will join the company on September 9 as Executive Vice President and Chief Human Resources Officer. Prior to joining CVS Health, Capozzi served as Executive Vice President and Global Chief Human Resources Officer at McDonald's, overseeing the company’s global human resources operations and leading talent management, learning and development, total rewards, and corporate employee relations. Before McDonald's, Capozzi held senior human resources positions at Boeing, including Senior Vice President of Human Resources. Her earlier career included roles in human resources functions at both large and small companies in the defense and automotive industries.

Perriquet

Perrigo, an Israeli chemical company, announced that it has added a brand-new position to its senior executive team: Chief Brand and Digital Officer, a role equivalent to Executive Vice President. The first person to take on this role is Dr. David Ball, who will be responsible for the company’s overall marketing strategy, including exploring new opportunity areas in the market and establishing consumer-facing branding initiatives. Dr. David Ball joined Bayer in 2019 as Senior Marketing Director for the Consumer Health business, after which he held other marketing leadership roles at Care/of (a now-defunct vitamin and supplement subscription service) and in Bayer's U.S. digestive health business.

Endo

Endo CEO Blaise Coleman Announces Departure After Successfully Guiding the Company Out of Bankruptcy

BioAge Labs

BioAge Labs Announces Jean-Pierre Garnier, Former CEO of GlaxoSmithKline (GSK), Joins as Chairman of the Board. Garnier served as CEO of GSK from 2000 to 2008. After leaving GSK, Garnier was CEO of Pierre Fabre for two years. Subsequently, Garnier held board positions at several biotech companies, including Actelion, Cellectis, and Idorsia. Founded in 2015, BioAge Labs gained prominence in 2020 by raising $90 million to treat aging and age-related diseases. In February this year, BioAge raised another $170 million in a Series D funding round to develop a new generation of oral weight-loss drugs and protect muscle mass.